We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Glucose Meter Evaluated for Neonatal Intensive Care

By LabMedica International staff writers
Posted on 17 Oct 2013
Print article
Image: StatStrip Glucose Meter (Photo courtesy of Nova Biomedical).
Image: StatStrip Glucose Meter (Photo courtesy of Nova Biomedical).
The monitoring of blood glucose in neonatal intensive care unit (NICU) patients is important in maintaining normoglycemia and reducing the risk of hypoglycemia.

Point-of-care testing (POCT) glucose meters provide short turnaround times but some have been reported to be affected by hematocrit interference and other biochemical or biological substances in their accuracy and performance.

Scientists at the Medical University of Vienna (Austria) tested 159 heparinized whole blood samples from NICU patients obtained for blood gas analysis. Accuracy (bias) of a new meter and analytical interferences were evaluated by comparing the results of the meter with the results of the blood gas analyzer routinely used for glucose measurements in this NICU setting.

Routine glucose measurements were performed at each hospital site using blood gas analyzers ABL 700 and ABL 835 (Radiometer Medical ApS, Copenhagen, Denmark). The blood gas analyzers were considered the appropriate reference method for comparing the performance of StatStrip Glucose POCT (Nova Biomedical; Waltham, MA, USA).

The results of glucose values covered the range of hypoglycemia to hyperglycemia, with glucose concentrations ranging from 13 mg/dL to 389 mg/dL. The results obtained for the Nova StatStrip Glucose POCT were not affected by the level of hematocrit, by sample pH or by medication. In the two children’s hospitals where the study was performed, the NICU patient population demonstrated a wide range of hematocrit levels even beyond the levels of the ranges claimed as not showing interferences in the product labeling of other glucose meters.

The authors concluded that the accuracy of the NOVA StatStrip Glucose meter results was not influenced by the varying hematocrit levels in the NICU patients, which validates the performance of the hematocrit correction that is in-built into the design of StatStrip Glucose. The StatStrip meter showed good clinical accuracy and performance for measuring and monitoring glucose levels in NICU patients, with special respect to preterm infants, and therefore can act as a perfect alternative to a blood gas analyzer for measuring blood glucose in NICU patients. The study was published on September 1, 2013, in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Medical University of Vienna
Radiometer Medical ApS
Nova Biomedical

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.